» Articles » PMID: 28476031

New Tumor Suppressor MicroRNAs Target Glypican-3 in Human Liver Cancer

Abstract

Glypican-3 (GPC3) is an oncogene, frequently upregulated in liver malignancies such as hepatocellular carcinoma (HCC) and hepatoblastoma and constitutes a potential molecular target for therapy in liver cancer. Using a functional screening system, we identified 10 new microRNAs controlling GPC3 expression in malignant liver cells, five of them e.g. miR-4510, miR-203a-3p, miR-548aa, miR-376b-3p and miR-548v reduce GPC3 expression. These 5 microRNAs were significantly downregulated in tumoral compared to non-tumoral liver and inhibited tumor cell proliferation. Interestingly, miR-4510 inversely correlated with GPC3 mRNA and protein in HCC samples. This microRNA also induced apoptosis of hepatoma cells and blocked tumor growth in vivo in the chick chorioallantoic membrane model. We further show that the tumor suppressive effect of miR-4510 is mediated through direct targeting of GPC3 mRNA and inactivation of Wnt/β-catenin transcriptional activity and signaling pathway. Moreover, miR-4510 up-regulated the expression of several tumor suppressor genes while reducing the expression of other pro-oncogenes. In summary, we uncovered several new microRNAs targeting the oncogenic functions of GPC3. We provided strong molecular, cellular and in vivo evidences for the tumor suppressive activities of miR-4510 bringing to the fore the potential value of this microRNA in HCC therapy.

Citing Articles

Non-coding RNAs participate in interactions between senescence and gastrointestinal cancers.

Liu Z, Ji F, Piao Y Front Genet. 2025; 15():1461404.

PMID: 39831201 PMC: 11739115. DOI: 10.3389/fgene.2024.1461404.


Characterization of an Activated Metabolic Transcriptional Program in Hepatoblastoma Tumor Cells Using scRNA-seq.

Monge C, Frances R, Marchio A, Pineau P, Desterke C, Mata-Garrido J Int J Mol Sci. 2024; 25(23).

PMID: 39684755 PMC: 11641740. DOI: 10.3390/ijms252313044.


The role of glypican-3 in hepatocellular carcinoma: Insights into diagnosis and therapeutic potential.

Devan A, Nair B, Pradeep G, Alexander R, Vinod B, Nath L Eur J Med Res. 2024; 29(1):490.

PMID: 39369212 PMC: 11453014. DOI: 10.1186/s40001-024-02073-2.


The preliminary data of gene expressions and bioinformatics analysis of miR-146b-5p and miR-4510 in the Turkish population in HBV-related hepatocellular carcinoma.

Kadioglu D, Demirtas C, Pirim D, Dilber F, Eren F Hepatol Forum. 2024; 5(3):106-112.

PMID: 39006138 PMC: 11237244. DOI: 10.14744/hf.2023.2023.0054.


The Role of microRNAs in Regulating Cancer Cell Response to Oxaliplatin-Containing Regimens.

Tavakoli Pirzaman A, Ebrahimzadeh Pirshahid M, Babajani B, Rahmati A, Niknezhad S, Hosseinzadeh R Technol Cancer Res Treat. 2023; 22:15330338231206003.

PMID: 37849311 PMC: 10586010. DOI: 10.1177/15330338231206003.


References
1.
Labbe E, Letamendia A, Attisano L . Association of Smads with lymphoid enhancer binding factor 1/T cell-specific factor mediates cooperative signaling by the transforming growth factor-beta and wnt pathways. Proc Natl Acad Sci U S A. 2000; 97(15):8358-63. PMC: 26952. DOI: 10.1073/pnas.150152697. View

2.
Hagedorn M, Javerzat S, Gilges D, Meyre A, de Lafarge B, Eichmann A . Accessing key steps of human tumor progression in vivo by using an avian embryo model. Proc Natl Acad Sci U S A. 2005; 102(5):1643-8. PMC: 547849. DOI: 10.1073/pnas.0408622102. View

3.
Capurro M, Xiang Y, Lobe C, Filmus J . Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 2005; 65(14):6245-54. DOI: 10.1158/0008-5472.CAN-04-4244. View

4.
Luo J, Ren B, Keryanov S, Tseng G, Rao U, Monga S . Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology. 2006; 44(4):1012-24. PMC: 1769554. DOI: 10.1002/hep.21328. View

5.
Boyault S, Rickman D, De Reynies A, Balabaud C, Rebouissou S, Jeannot E . Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2006; 45(1):42-52. DOI: 10.1002/hep.21467. View